Search results
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Morningstar· 6 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive ...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks· 3 days agoBiogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...
Morningstar· 3 days agoBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks· 6 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From...
WKRN Nashville· 5 days agoBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoAffimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company’ ...